Healthleap Raises $38M to Expand Inpatient Risk AI

Hospitals produce more clinical evidence than a bedside team can read before morning rounds. Lab values sit in structured fields, clues such as poor appetite or trouble swallowing hide inside notes, and a patient can remain unseen even when the record already contains the warning.

Healthleap has raised $38M to narrow that gap. The financing combines an $8M Seed round co-led by Sequoia Capital and First Round Capital with a $30M Series A led by Hummingbird Ventures. The company is using the capital to expand an EHR-native risk-screening platform that prioritizes patients for clinical review, starting with malnutrition and extending toward other frequently missed conditions.

What Healthleap Raised

The October 7 announcement covers two financing events rather than one $38M Series A. Sequoia Capital and First Round Capital co-led the $8M Seed, while Hummingbird Ventures led the $30M Series A. Healthleap did not disclose its valuation.

Healthleap also raised a $1.1M pre-seed led by Fifty Years in 2022, bringing publicly disclosed lifetime funding to $39.1M. The company says the new capital will support engineering, product, sales, and customer success as it adds condition-specific programs and grows across more health systems.

Siblings Josiah Meyer and Jemima Meyer founded Healthleap after Jemima, a clinical dietitian, built an earlier tool to help colleagues find and treat patients faster. Josiah Meyer is co-founder and CEO. The current leadership team also includes Richard Riggs, MD, as Chief Medical Officer after he previously served in that role at Cedars-Sinai.

From a Dietitian's Tool to an Inpatient Risk Layer

Healthleap connects to a hospital's electronic health record and analyzes structured information such as labs, vitals, weights, medications, orders, and diagnoses alongside written clinical notes. Each morning, it writes risk scores into the care team's existing workflow so clinicians can review higher-risk patients earlier.

The distinction between prioritization and diagnosis matters. Healthleap's software highlights patients who may need additional attention; clinicians still make the assessment and care decisions. That keeps the product focused on an operational problem hospitals recognize immediately: the evidence may exist, but staffing and workflow limits prevent every chart from receiving the same depth of review at the same time.

Malnutrition became the first condition because Jemima Meyer had lived that gap in clinical practice. It also gave Healthleap a measurable starting point, where the company could compare its model with an established nurse-administered screening process and track whether patients were identified earlier.

The Evidence Behind the Starting Wedge

A 2025 peer-reviewed study in Applied Clinical Informatics evaluated Healthleap's malnutrition model across more than 166,000 admissions from more than 106,000 patients over 3.75 years. The company reports an area under the receiver operating characteristic curve of 0.92 on day one and 0.95 across the hospital stay. It also reports 88% higher sensitivity than the modified Malnutrition Screening Tool and identification a mean of four days before initial dietitian documentation.

Those findings apply to the malnutrition screening model, not every condition on Healthleap's roadmap. The company has built or is testing programs for delirium and toxic metabolic encephalopathy, aspiration pneumonia, pressure injuries, and congestive-heart-failure readmission risk. Each expansion adds addressable need, but it also adds a fresh validation obligation.

Healthleap says its platform is now deployed in more than 50 hospitals, up from three hospital partners in the prior year. Named customers and partners include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare. TechCrunch reported company-reported revenue growth of more than 10x over the same period, without a disclosed revenue base.

Why Hospitals Can Measure the Economics

Earlier identification can affect several hospital outcomes at once. A patient may receive appropriate nutrition care sooner, the hospital may document the severity of the case more accurately, and a shorter stay can return scarce bed capacity to the system.

On its evidence page, Healthleap reports $23.8M in annualized financial impact at one Penn Medicine hospital. The company breaks that figure into $6.3M in additional reimbursement and $17.5M in length-of-stay impact associated with 8,632 annualized bed-days saved. Healthleap says Penn Medicine's Strategic Decision Support team validated the analysis.

That result should not be treated as a universal forecast for every hospital. It does show why the sales conversation can include clinical, informatics, finance, and operational leaders around one workflow. Healthleap is selling earlier attention, but the buyer can measure the result through care delivery, reimbursement, length of stay, and capacity.

What the $38M Changes

Healthleap's next phase is broader than hiring more people to sell the existing malnutrition product. CEO Josiah Meyer told TechCrunch that the company ultimately wants to cover more than 40 major conditions and expand from inpatient settings into outpatient and home care.

That ambition changes the operating burden. A model that performs well for one condition at one group of hospitals does not automatically transfer its evidence, workflow fit, or clinical acceptance to another condition. Healthleap has to repeat the work of defining the signal, validating the model, integrating the output, and proving that the intervention helps the right team act at the right time.

The current hiring plan reflects that expansion. Healthleap's careers site describes a roughly 25-person team and active growth across the functions needed to build, deploy, and support clinical software. The financing gives the company room to pursue the next condition without treating the first validation as a permanent permission slip.

The Market Signal Behind Healthleap's Round

Healthcare AI has spent years proving that software can produce another prediction, note, summary, or recommendation. Healthleap is working on the harder handoff between prediction and attention: where the signal appears, who trusts it, and whether it arrives early enough to change care.

Hummingbird Ventures, Sequoia Capital, and First Round Capital are underwriting that handoff as a scalable software category. The investment case depends on Healthleap making each new condition legible to clinicians and measurable to hospital operators without turning the workflow into another screen competing for attention.

The $38M gives Healthleap more capacity to build that broader layer. The clinical record will keep growing either way. The company's opportunity lives in reducing the time between what the chart can already reveal and when the right person is finally able to see it.